公开(公告)号：US06703206B2

公开(公告)日：2004-03-09

申请号：US09915031

申请日：2001-07-25

申请人： Keshab D. Pant ,  John D. McCracken ,  Omar Fagoaga ,  Wayne Kelln ,  Sandra Nehlsen-Cannarella

发明人： Keshab D. Pant ,  John D. McCracken ,  Omar Fagoaga ,  Wayne Kelln ,  Sandra Nehlsen-Cannarella

IPC分类号： G01N3353

CPC分类号： G01N33/57419 ,  Y10S435/975

摘要： An immunological assay and kit for colon cancer screening is disclosed. Fecal glycoproteins are extracted from individual samples such that immunogenicity is maintained. The purified fecal glycoproteins are reacted with antibodies to Colon and Ovarian Tumor Antigen (COTA). The mucin antigen COTA is specifically present in colorectal cancer tissue and not in normal colons. The amount of COTA in the fecal sample is determined and used to indicate the presence of colon cancer.

公开(公告)号：US20050260669A1

公开(公告)日：2005-11-24

申请号：US11174166

申请日：2005-07-01

申请人： Wolff Kirsch ,  Anton Lennart ,  Wayne Kelln ,  Dae-Kyung Kang ,  Rodney Levine ,  Tracey Rouault

发明人： Wolff Kirsch ,  Anton Lennart ,  Wayne Kelln ,  Dae-Kyung Kang ,  Rodney Levine ,  Tracey Rouault

IPC分类号： C12N15/09 ,  C07K14/00 ,  C07K14/47 ,  C07K16/18 ,  C12P21/08 ,  C12Q1/68 ,  C12Q1/6883 ,  G01N33/53 ,  G01N33/567 ,  C07H21/04 ,  C12P21/06 ,  C07K14/705 ,  C07K16/28

CPC分类号： G01N33/6896 ,  C07K14/4702 ,  C07K16/18 ,  C12Q1/6883 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N2800/04 ,  G01N2800/2821

摘要： The present invention relates to the discovery of markers for neurodegenerative disease. More particularly, it was discovered that forms of IRP-2 protein that are unable to undergo oxidation at critical cysteine residues are diagnostic for neurodegenerative disease including, but not limited to Alzheimer's disease. Embodiments include nucleic acids that encode mutant IRP-2 proteins and fragments thereof, mutant IRP-2 proteins and fragments thereof, antibodies directed to epitopes present on mutant IRP-2 proteins and fragments thereof, methods of making these nucleic acids and polypeptides, as well as, approaches to diagnose neurodegenerative disease in animals, such as humans at risk of contracting Alzheimer's disease.

摘要翻译： 本发明涉及神经变性疾病标记物的发现。 更具体地，已经发现，不能在关键半胱氨酸残基处经历氧化的IRP-2蛋白的形式是神经变性疾病的诊断，包括但不限于阿尔茨海默病。 实施方案包括编码突变体IRP-2蛋白及其片段，突变体IRP-2蛋白及其片段的核酸，针对存在于突变体IRP-2蛋白及其片段上的表位的抗体，以及制备这些核酸和多肽的方法 作为诊断动物中的神经变性疾病的方法，例如患有阿尔茨海默病的风险的人。

公开(公告)号：US20080020393A1

公开(公告)日：2008-01-24

申请号：US11769503

申请日：2007-06-27

申请人： Wolff Kirsch ,  Anton Lennart ,  Wayne Kelln ,  Dae-Kyung Kang ,  Rodney Levine ,  Tracey Rouault

发明人： Wolff Kirsch ,  Anton Lennart ,  Wayne Kelln ,  Dae-Kyung Kang ,  Rodney Levine ,  Tracey Rouault

IPC分类号： C12Q1/68 ,  G01N33/567

CPC分类号： G01N33/6896 ,  C07K14/4702 ,  C07K16/18 ,  C12Q1/6883 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N2800/04 ,  G01N2800/2821

摘要： The present invention relates to the discovery of markers for neurodegenerative disease. More particularly, it was discovered that forms of IRP-2 protein that are unable to undergo oxidation at critical cysteine residues are diagnostic for neurodegenerative disease including, but not limited to Alzheimer's disease. Embodiments include nucleic acids that encode mutant IRP-2 proteins and fragments thereof, mutant IRP-2 proteins and fragments thereof, antibodies directed to epitopes present on mutant IRP-2 proteins and fragments thereof, methods of making these nucleic acids and polypeptides, as well as, approaches to diagnose neurodegenerative disease in animals, such as humans at risk of contracting Alzheimer's disease.

摘要翻译： 本发明涉及神经变性疾病标记物的发现。 更具体地，已经发现，不能在关键半胱氨酸残基处经历氧化的IRP-2蛋白的形式是神经变性疾病的诊断，包括但不限于阿尔茨海默病。 实施方案包括编码突变体IRP-2蛋白及其片段，突变体IRP-2蛋白及其片段的核酸，针对存在于突变体IRP-2蛋白及其片段上的表位的抗体，以及制备这些核酸和多肽的方法 作为诊断动物中的神经变性疾病的方法，例如患有阿尔茨海默病的风险的人。

公开(公告)号：US06531319B1

公开(公告)日：2003-03-11

申请号：US09567748

申请日：2000-05-10

申请人： Keshab D. Pant ,  John D. McCracken ,  Omar Fagoaga ,  Wayne Kelln ,  Sandra Nehlsen-Cannarella

发明人： Keshab D. Pant ,  John D. McCracken ,  Omar Fagoaga ,  Wayne Kelln ,  Sandra Nehlsen-Cannarella

IPC分类号： G01N3348

CPC分类号： G01N33/57419 ,  Y10S435/975

摘要： An immunological assay and kit for colon cancer screening is disclosed. Fecal glycoproteins are extracted from individual samples such that immunogenicity is maintained. The purified fecal glycoproteins are reacted with antibodies to Colon and Ovarian Tumor Antigen (COTA). The mucin antigen COTA is specifically present in colorectal cancer tissue and not in normal colons. The amount of COTA in the fecal sample is determined and used to indicate the presence of colon cancer.

公开(公告)号：US07252955B2

公开(公告)日：2007-08-07

申请号：US10721434

申请日：2003-11-25

申请人： Keshab D. Pant ,  John D. McCracken ,  Omar Fagoaga ,  Wayne Kelln ,  Sandra Nehlsen-Cannarella

发明人： Keshab D. Pant ,  John D. McCracken ,  Omar Fagoaga ,  Wayne Kelln ,  Sandra Nehlsen-Cannarella

IPC分类号： G01N33/53

CPC分类号： G01N33/57419 ,  Y10S435/975

摘要： An immunological assay and kit for colon cancer screening is disclosed. Fecal glycoproteins are extracted from individual samples such that immunogenicity is maintained. The purified fecal glycoproteins are reacted with antibodies to Colon and Ovarian Tumor Antigen (COTA). The mucin antigen COTA is specifically present in colorectal cancer tissue and not in normal colons. The amount of COTA in the fecal sample is determined and used to indicate the presence of colon cancer.

摘要翻译： 公开了用于结肠癌筛选的免疫学测定和试剂盒。 从各个样品中提取粪便糖蛋白，从而保持免疫原性。 纯化的粪便糖蛋白与结肠和卵巢肿瘤抗原（COTA）的抗体反应。 粘蛋白抗原COTA特异性存在于结肠直肠癌组织中，而不是正常的冒号。 确定粪便样品中COTA的量并用于指示结肠癌的存在。